Table 5 Documented delivery of clinical care
| Â | Risk classification1 | 2008 | 2009 | 2010 | p value |
|---|---|---|---|---|---|
Received 80% + of scheduled injections | All | 25% (29/116) | 26% (25/97) | 23% (24/103) | 0.78 |
High/Med | 30% (17/57) | 32% (14/44) | 28% (13/47) | 0.83 | |
Received 60% + of scheduled injections | All | 42% (49/116) | 53% (51/97) | 52% (54/103) | 0.13 |
Received 40% + of scheduled injections | All | 70% (81/116) | 76% (74/97) | 82% (84/103) | 0.04 |
Frequency of BPG injections scheduled at four weekly | All people with documented requirement for regular BPG injections | 20% (23/116) | 32% (31/97) | 52% (54/103) | <0.001 |
Actions to improve uptake for people who received <80% of injections | Active recall | 81% 70/86 | 94% 68/72 | 89% 70/79 | 0.15 |
Arrange BPG if out of community | 59% 51/86 | 62% 45/72 | 63% 50/79 | 0.60 | |
Prevention advice | 64% 55/86 | 76% 38/72 | 39% 31/79 | 0.002 | |
Family meeting | 31% 27/86 | 17% 12/72 | 8% 6/79 | <0.001 | |
Action plan | 28% 24/86 | 18% 13/72 | 5% 4/79 | <0.001 | |
Additional measures after first active recall (home visits, delivery of written reminders, phone text messages) | 27% 23/86 | 24% 17/72 | 46% 36/79 | 0.01 | |
Active recall plus at least one other of the above strategies | for people who received <80% of injections | 69% 59/86 | 85% 61/72 | 72% 57/79 | 0.56 |
Echocardiogram | all within three years | 55% (85/154) | 60% (87/145) | 62% (97/156) | 0.21 |
high and medium risk within 12Â months1 | 39% (23/69) | 42% (22/52) | 44% (27/61) | 0.20 | |
Documented review by doctor | All within 2Â years | 73% (112/154) | 83% (121/145) | 86% (134/156) | 0.003 |
within 6Â months | High/medium | 46% (34/69) | 67% (35/52) | 74% (45/61) | 0.004 |
within 12Â months | Low/undetermined | 58% (49/85) | 71% (66/93) | 66% (63/95) | 0.24 |
Documented dental review | all within 2Â years | 11% (17/154) | 20% (29/154) | 16% (25/156) | 0.26 |
High/medium within 12Â months | 10% (7/69) | 21% (11/52) | 18% (11/61) | 0.21 | |
Documented review by cardiologist/physician | All within 2Â years | 51% (78/154) | 49% (71/145) | 56% (87/156) | 0.36 |
High/medium within 12Â months2 | 39% (27/69) | 48% (25/52) | 43% (26/61) | 0.66 | |
Influenza immunisation within 12Â months | All | 37% (57/154) | 54% (78/145) | 55% (86/156) | 0.001 |
High/medium | 38% (26/69) | 58% (30/52) | 61% (37/61) | 0.008 | |
Pneumovax - at least three doses since birth | All | 0% (0/154) | 0% (0/145) | 13% (21/156) | n/a |
High/medium | 0% (0/69) | 0% (0/52) | 20% (12/61) | n/a | |
Record of provision of educational materials about rheumatic fever (DVD/video/written materials) | All | 6% (9/154) | 6% (9/145) | 1% (2/156) | 0.06 |
Prescribed warfarin | High/medium | 20% (14/69) | 31% (16/52) | 26% (16/61) | 0.41 |
INR testing | For those on Warfarin (at least two INRs in past 6Â months) | 100% | 100% | 100% | n/a |
INR result | Of those with test results, % within recommended range | 64% (9/14) | 69% (11/16) | 75% (12/16) | 0.52 |